HFM
FENC icon

Hartford Financial Management’s Fennec Pharmaceuticals FENC Stock Holding History

Hartford Financial Management’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$311K Hold
50,646
– – 0.08% 118
2025
Q4 		$390K Hold
50,646
– – 0.1% 113
2025
Q3 		$474K Hold
50,646
– – 0.13% 107
2025
Q2 		$420K Buy
50,646
+798
+2% +$5.46K 0.11% 112
2025
Q1 		$304K Hold
49,848
– – 0.06% 146
2024
Q4 		$315K Buy
49,848
+1,000
+2% +$5.12K 0.06% 145
2024
Q3 		$244K Hold
48,848
– – 0.05% 151
2024
Q2 		$298K Buy
48,848
+1,050
+2% +$8.72K 0.06% 144
2024
Q1 		$532K Buy
47,798
+450
+1% +$4.52K 0.11% 130
2023
Q4 		$531K Buy
47,348
+2,000
+4% +$16.6K 0.12% 130
2023
Q3 		$341K Hold
45,348
– – 0.09% 142
2023
Q2 		$400K Buy
45,348
+4,000
+10% +$33.3K 0.1% 139
2023
Q1 		$344K Buy
41,348
+1,500
+4% +$13.9K 0.09% 140
2022
Q4 		$383K Hold
39,848
– – 0.1% 136
2022
Q3 		$323K Buy
39,848
+5,000
+14% +$34.3K 0.09% 139
2022
Q2 		$197K Hold
34,848
– – 0.05% 151
2022
Q1 		$195K Hold
34,848
– – 0.05% 150
2021
Q4 		$153K Buy
34,848
+6,000
+21% +$44.7K 0.04% 159
2021
Q3 		$272K Hold
28,848
– – 0.07% 141
2021
Q2 		$210K Sell
28,848
-5,000
-15% -$33.4K 0.05% 148
2021
Q1 		$210K Sell
33,848
-5,000
-13% -$37.6K 0.05% 146
2020
Q4 		$289K Hold
38,848
– – 0.08% 138
2020
Q3 		$235K Sell
38,848
-10,700
-22% -$75.4K 0.07% 138
2020
Q2 		$414K Buy
49,548
+7,400
+18% +$55K 0.13% 121
2020
Q1 		$250K Buy
42,148
+7,148
+20% +$46.6K 0.1% 126
2019
Q4 		$227K Buy
35,000
+5,000
+17% +$26.9K 0.07% 145
2019
Q3 		$144K Buy
30,000
+9,700
+48% +$42.8K 0.05% 169
2019
Q2 		$81K Buy
20,300
+8,000
+65% +$33.9K 0.03% 188
2019
Q1 		$60K Buy
12,300
+2,300
+23% +$15.1K 0.02% 203
2018
Q4 		$64K Hold
10,000
– – 0.02% 200
2018
Q3 		$82K Sell
10,000
-1,000
-9% -$9.28K 0.03% 200
2018
Q2 		$115K Buy
11,000
+2,000
+22% +$23.7K 0.04% 183
2018
Q1 		$108K Buy
9,000
+6,850
+319% +$64.7K 0.05% 153
2017
Q4 		$21K Buy
2,150
+1,000
+87% +$9.98K 0.01% 218
2017
Q3 		$12K Buy
+1,150
New +$13.4K 0.01% 282

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

Hartford Financial Management's FENC Position: Q1 2026 in Review

Hartford Financial Management held its Fennec Pharmaceuticals (FENC) position steady in Q1 2026 at 50,646 shares worth $311K. The position accounts for 0.08% of the portfolio, ranked #118.

Hartford Financial Management first reported a position in FENC in Q3 2017 and has held it in 35 quarters since. The position peaked at $532K in Q1 2024. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • Hartford Financial Management held 50,646 shares of Fennec Pharmaceuticals worth $311K as of Q1 2026.
  • Hartford Financial Management left its Fennec Pharmaceuticals share count unchanged in Q1 2026.
  • Fennec Pharmaceuticals made up 0.08% of Hartford Financial Management's portfolio in Q1 2026, its #118 holding.
  • Hartford Financial Management first reported a position in Fennec Pharmaceuticals in Q3 2017 and has held it in 35 quarters since.
  • Hartford Financial Management's Fennec Pharmaceuticals position peaked at $532K in Q1 2024.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Hartford Financial Management's 13F filing for Q1 2026, filed 16 Apr 2026.